Oncotarget

Reviews:

Naturally occurring compounds as pancreatic cancer therapeutics

Ines Lohse _, Erin Wildermuth and Shaun P. Brothers

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:35448-35457. https://doi.org/10.18632/oncotarget.26234

Metrics: PDF 587 views  |   HTML 1269 views  |   ?  


Abstract

Ines Lohse1,2,*, Erin Wildermuth1,* and Shaun P. Brothers1,2

1Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation University of Miami Miller School of Medicine, University of Miami, Miami, FL, USA

2Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

*These authors equally contributed to the work

Correspondence to:

Ines Lohse, email: ixl180@med.miami.edu

Shaun P. Brothers, email: sbrothers@med.miami.edu

Keywords: pancreatic cancer; natural compounds; curcumin; resveratrol; taxane

Received: August 26, 2018     Accepted: October 06, 2018     Published: October 23, 2018

ABSTRACT

Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26234